Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.

Détails

ID Serval
serval:BIB_B9A6ED2EDBC0
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.
Périodique
Nature Clinical Practice. Oncology
Auteur⸱e⸱s
Ganière V., Christen G., Bally F., Guillou L., Pica A., de Ribaupierre S., Stupp R.
ISSN
1743-4254
Statut éditorial
Publié
Date de publication
2006
Peer-reviewed
Oui
Volume
3
Numéro
6
Pages
339-343; quiz following 343
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Résumé
BACKGROUND: A 55-year-old man with glioblastoma multiforme was treated with continuous, dose-dense temozolomide. This therapy was curtailed after three cycles because of nausea, asthenia, and neuropsychological deterioration. During a subsequent course of radiotherapy, the patient developed fever, headaches, and cutaneous lesions. INVESTIGATIONS: Physical examination, cerebral MRI, brain biopsy, skin biopsy, immunohistochemistry, bronchoscopy with bronchoalveolar lavage, and laboratory tests. DIAGNOSIS: Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. MANAGEMENT: Discontinuation of temozolomide, discontinuation of radiotherapy, antibiotic treatment with amoxicillin and gentamicin, and administration of atovaquone and pentamidine.
Mots-clé
Antineoplastic Agents, Alkylating, Brain Abscess, Brain Neoplasms, Dacarbazine, Glioblastoma, Humans, Listeria Infections, Male, Middle Aged, Neoadjuvant Therapy, Pneumocystis jirovecii, Pneumonia, Pneumocystis, Sarcoma, Kaposi
Pubmed
Web of science
Création de la notice
25/04/2008 9:22
Dernière modification de la notice
20/08/2019 16:27
Données d'usage